Boston Scientific Co. (NYSE:BSX) Shares Purchased by Ashton Thomas Securities LLC

Ashton Thomas Securities LLC raised its position in Boston Scientific Co. (NYSE:BSX) by 3.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 10,316 shares of the medical equipment provider’s stock after buying an additional 348 shares during the quarter. Ashton Thomas Securities LLC’s holdings in Boston Scientific were worth $921,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of BSX. Advisors Asset Management Inc. raised its holdings in Boston Scientific by 21.3% during the third quarter. Advisors Asset Management Inc. now owns 24,060 shares of the medical equipment provider’s stock worth $2,016,000 after purchasing an additional 4,233 shares in the last quarter. Nwam LLC acquired a new position in Boston Scientific during the 3rd quarter worth approximately $294,000. Great Valley Advisor Group Inc. raised its stake in shares of Boston Scientific by 2.7% during the 3rd quarter. Great Valley Advisor Group Inc. now owns 40,455 shares of the medical equipment provider’s stock worth $3,390,000 after buying an additional 1,074 shares in the last quarter. Kingsview Wealth Management LLC raised its stake in shares of Boston Scientific by 5.0% during the 3rd quarter. Kingsview Wealth Management LLC now owns 5,970 shares of the medical equipment provider’s stock worth $500,000 after buying an additional 282 shares in the last quarter. Finally, Swedbank AB lifted its holdings in shares of Boston Scientific by 0.6% in the 3rd quarter. Swedbank AB now owns 1,430,925 shares of the medical equipment provider’s stock valued at $119,912,000 after buying an additional 8,246 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $102.74 on Tuesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The company has a market cap of $151.96 billion, a PE ratio of 82.19, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. The company has a 50-day simple moving average of $101.84 and a 200-day simple moving average of $92.65. Boston Scientific Co. has a 12 month low of $66.80 and a 12 month high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, equities analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on BSX. Royal Bank of Canada increased their price objective on Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Raymond James increased their price target on shares of Boston Scientific from $119.00 to $122.00 and gave the company a “strong-buy” rating in a report on Thursday, February 6th. Stifel Nicolaus raised their price objective on shares of Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Truist Financial upped their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research report on Friday, January 10th. Two investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $108.91.

Insider Buying and Selling

In other news, EVP John Bradley Sorenson sold 1,201 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $106.31, for a total transaction of $127,678.31. Following the transaction, the executive vice president now directly owns 25,443 shares in the company, valued at $2,704,845.33. This represents a 4.51 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Daniel J. Brennan sold 15,087 shares of the business’s stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the completion of the sale, the chief financial officer now owns 241,451 shares of the company’s stock, valued at approximately $25,369,256.57. The trade was a 5.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 137,302 shares of company stock worth $14,319,269. 0.50% of the stock is owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.